Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antidepressant DTC Ads Must Disclose New Risk Information Within 30 Days

This article was originally published in The Pink Sheet Daily

Executive Summary

Antidepressant manufacturers have 30 days to bring their direct-to consumer ads into compliance following FDA's approval of a "black box" class warning

You may also be interested in...

FDA Approves Antidepressant "Black Box" Class Labeling

The revised labeling should be available on manufacturers' web pages within two weeks and on all products within 30 days, FDA says. Medication Guides should be available to pharmacists by Jan. 31, the agency says.

Antidepressant “Black Box” Warning For Pediatric Suicidality Risk Recommended

“Black box” warning would encourage discussion of risks and benefits of antidepressant therapy in children by physicians, FDA advisory committee members say. Warning likely to affect direct-to-consumer advertising, FDA notes. Committee members recommend class warning for all antidepressants, including new products.

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts